Clinical Responses to Tarlatamab Among Patients with Pulmonary Carcinoid.

Authors

Jessica S Ross, Jake Lee, Eduardo Ortiz, Onur Yildirim, Rania G Aly, Prithviraj Solanki, Natasha Rekhtman, Charles M Rudin

Published in

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Pages 104135. Aug 06, 2026. Epub Aug 06, 2026.

Abstract

Pulmonary carcinoid (PC) is a rare, well-differentiated neuroendocrine tumor of the lung. In patients with metastatic disease, systemic therapies typically have low response rates, and long-term survival is poor. PC frequently expresses DLL3, but whether it responds to the DLL3-targeted bispecific T-cell engager tarlatamab is unknown.
We analyzed 11 patients with DLL3-high PC treated with tarlatamab at Memorial Sloan Kettering. Tumor response was assessed using RECIST v 1.1.
Response rate was 8/11 (73%), including one patient with central nervous system-only disease, and disease control rate was 11/11 (100%). All patients experienced reduction of their measurable disease. One patient had progressed at time of data cutoff and median progression-free survival was not reached. Cytokine release syndrome (CRS) occurred in cycle 1 in 9/11 (82%) patients including 2 with grade 3 CRS.
Tarlatamab demonstrated a high response rate in PC. Cytokine release syndrome was common. Tarlatamab is a promising treatment option for patients with PC.

PMID:
42562260
Bibliographic data and abstract were imported from PubMed on 07 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.